Recce Pharmaceuticals Ltd: Appendix 4G
Recce Pharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Recce Pharmaceuticals Ltd: US Department of Defense Grants US $2m for R327G
Recce Pharmaceuticals Ltd: Change of Auditor
Recce Pharmaceuticals Ltd: R327 Efficacy against WHO Priority Pathogen Acinetobacter B
Recce Pharmaceuticals Ltd: Trading Halt
Recce Pharmaceuticals Ltd: Clarification - Phase I/II UTI/Urosepsis Fast Infusion Trial
Recce Pharmaceuticals Ltd: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
Recce Pharmaceuticals Ltd: Ethics Approval Broadens to All Topical Infections
Recce Pharmaceuticals Ltd: Further R&D Rebate Approved
Recce Pharmaceuticals Ltd: R327 added to WHO List of Antibacterial Products
Recce Pharmaceuticals Ltd: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
Recce Pharmaceuticals Ltd: Military Health Research Symposium Abstract & Presentation
Recce Pharmaceuticals Ltd: Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort
Recce Pharmaceuticals Ltd: MCRI Pilot Study- Positive Efficacy Data for Lung Infections
Recce Pharmaceuticals Ltd: China Patent Granted for RECCE Anti-Infectives
Recce Pharmaceuticals Ltd: Safety Committee Approves High Dose of 4,000mg
Recce Pharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Recce Pharmaceuticals Ltd: Recce Completes 5,000 R327 Doses Per Week under GMP
Recce Pharmaceuticals Ltd: Recce Pharmaceuticals - Business Update
No Data